Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin.
Minerva Endocrinol
; 37(1): 25-40, 2012 Mar.
Article
em En
| MEDLINE
| ID: mdl-22382613
ABSTRACT
Metformin is a widely used and extensively studied insulin sensitising drug for the treatment of women with polycystic ovary syndrome (PCOS), with various actions in tissues responding to insulin that include the liver, skeletal muscle, adipose tissue, the endothelium of blood vessels, and the ovaries. Treatment of PCOS women with metformin has been shown to reduce fasting glucose levels, blood pressure, and serum androgens; further effects of metformin in women with PCOS may include direct effects on the central nervous system; and indirect effects via the modification of gut hormone and adipokine synthesis and/or secretion. A number of "novel" adipokines and metabolic factors have been recently identified which may play a role both in the pathogenesis and the treatment of women with PCOS. We here discuss recent advances in the area, with a focus on neuroendocrine and endocrine dysfunctions in women with PCOS and the potential role of metformin in this context.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Síndrome do Ovário Policístico
/
Sistema Endócrino
/
Hiperinsulinismo
/
Metformina
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
Limite:
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Minerva Endocrinol
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Reino Unido